| Guidelines for the use and interpretation of assays for monitoring autophagy DJ Klionsky, K Abdelmohsen, A Abe, MJ Abedin, H Abeliovich, ... Autophagy 12 (1), 1-222, 2016 | 10953* | 2016 |
| Guidelines for the use and interpretation of assays for monitoring autophagy HU Simon, M Tschan, P Bütikofer Autophagy 12 (1), 1-222, 2016 | 2931* | 2016 |
| Fluorouracil: biochemistry and pharmacology. HM Pinedo, GF Peters Journal of clinical oncology 6 (10), 1653-1664, 1988 | 1082 | 1988 |
| MRP3, an organic anion transporter able to transport anti-cancer drugs M Kool, M Van Der Linden, M de Haas, GL Scheffer, JML De Vree, ... Proceedings of the National Academy of Sciences 96 (12), 6914-6919, 1999 | 835 | 1999 |
| Comparison of the sulforhodamine B protein and tetrazolium (MTT) assays for in vitro chemosensitivity testing YP Keepers, PE Pizao, GJ Peters, J van Ark-Otte, B Winograd, HM Pinedo European Journal of Cancer and Clinical Oncology 27 (7), 897-900, 1991 | 640 | 1991 |
| Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2 JH Hooijberg, HJ Broxterman, M Kool, YG Assaraf, GJ Peters, ... Cancer Research 59 (11), 2532-2535, 1999 | 605 | 1999 |
| Molecular basis of bortezomib resistance: proteasome subunit β5 (PSMB5) gene mutation and overexpression of PSMB5 protein R Oerlemans, NE Franke, YG Assaraf, J Cloos, I van Zantwijk, CR Berkers, ... Blood, The Journal of the American Society of Hematology 112 (6), 2489-2499, 2008 | 544 | 2008 |
| MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity E Giovannetti, N Funel, GJ Peters, M Del Chiaro, LA Erozenci, E Vasile, ... Cancer research 70 (11), 4528-4538, 2010 | 533 | 2010 |
| Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism GJ Peters, HHJ Backus, S Freemantle, B Van Triest, G Codacci-Pisanelli, ... Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease 1587 (2-3 …, 2002 | 501 | 2002 |
| Determinants of resistance to 2′, 2′-difluorodeoxycytidine (gemcitabine) AM Bergman, HM Pinedo, GJ Peters Drug Resistance Updates 5 (1), 19-33, 2002 | 425 | 2002 |
| Guidelines for the use and interpretation of assays for monitoring autophagy DJ Klionsky, FC Abdalla, H Abeliovich, RT Abraham, A Acevedo-Arozena, ... Autophagy 8 (4), 445-544, 2012 | 404* | 2012 |
| Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer MM Borner, P Schöffski, R De Wit, F Caponigro, G Comella, A Sulkes, ... European Journal of Cancer 38 (3), 349-358, 2002 | 398 | 2002 |
| Basis for effective combination cancer chemotherapy with antimetabolites GJ Peters, CL Van der Wilt, CJA Van Moorsel, JR Kroep, AM Bergman, ... Pharmacology & therapeutics 87 (2-3), 227-253, 2000 | 396 | 2000 |
| 5-Fluorouracil incorporation into RNA and DNA in relation to thymidylate synthase inhibition of human colorectal cancers P Noordhuis, U Holwerda, CL Van der Wilt, CJ Van Groeningen, K Smid, ... Annals of oncology 15 (7), 1025-1032, 2004 | 392 | 2004 |
| Interaction between cisplatin and gemcitabine in vitro and in vivo. GJ Peters, AM Bergman, VW Ruiz van Haperen, G Veerman, CM Kuiper, ... Seminars in oncology 22 (4 Suppl 11), 72-79, 1995 | 376 | 1995 |
| Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance KJ Gotink, HJ Broxterman, M Labots, RR De Haas, H Dekker, ... Clinical Cancer Research 17 (23), 7337-7346, 2011 | 370 | 2011 |
| Synergistic interaction between cisplatin and gemcitabine in vitro. AM Bergman, VW Ruiz van Haperen, G Veerman, CM Kuiper, GJ Peters Clinical cancer research: an official journal of the American Association …, 1996 | 369 | 1996 |
| Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer JH Hwang, J Voortman, E Giovannetti, SM Steinberg, LG Leon, YT Kim, ... PloS one 5 (5), e10630, 2010 | 363 | 2010 |
| Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors BC Kuenen, L Rosen, EF Smit, MRN Parson, M Levi, R Ruijter, ... Journal of clinical oncology 20 (6), 1657-1667, 2002 | 363 | 2002 |
| 2′, 2′-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines VWTR van Haperen, G Veerman, JB Vermorken, GJ Peters Biochemical pharmacology 46 (4), 762-766, 1993 | 342 | 1993 |
Elisa GiovannettiAssociate Professor - UHD - Amsterdam UMC (VUmc) & FPS, PisaVerified email at vumc.nl
